Previous Winners

2021 - 8th World ADC Awards

Best ADC Pre-Clinical Publication 2021

Best Poster 2022

Winner: A bi-orthogonal system reveals antitumour immune function of pyroptosis.

Pyrop-tyosis

Wang Q, Wang Y, Ding J, Wang C, Zhou X, Gao W, Huang H, Shao F, Liu Z.Nature. 2020 Mar;579(7799):421-426. doi: 10.1038/s41586-020-2079-1. Epub 2020 Mar 11.PMID: 32188939

Citations: 106

Runner Up: Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.

Maneiro MA, Forte N, Shchepinova MM, Kounde CS, Chudasama V, Baker JR, Tate EW.ACS Chem Biol. 2020 Jun 19;15(6):1306-1312. doi: 10.1021/acschembio.0c00285. Epub 2020 Apr 30.PMID: 32338867

Citations: 30

Best ADC Clinical Publication 2021

Winner: Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators.N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.PMID: 31825192

Citations: 456

Runner Up: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ.J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6.PMID: 31693429

Citations: 206

Outstanding Academic Investigator

The George R. Pettit Individual Input to the Field 2020

2020 - 7th World ADC Awards

Best ADC Pre-Clinical Publication 2019

Winner:
Czechowicz A, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Pang WW, Mansour MK, Tate TA, Chan YY, Walck E, Wernig G, Shizuru JA, Winau F, Scadden DT, Rossi DJ. Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. Nat Commun. 2019 Feb 6;10(1):617. doi: 10.1038/s41467-018-08201-x. PMID: 30728354; PMCID: PMC6365495.

Runner Up:
Yamada K, Shikida N, Shimbo K, Ito Y, Khedri Z, Matsuda Y, Mendelsohn BA. AJICAP: Affinity Peptide Mediated Regiodivergent Functionalization of Native Antibodies. Angew Chem Int Ed Engl. 2019 Apr 16;58(17):5592-5597. doi: 10.1002/anie.201814215. Epub 2019 Mar 29. PMID: 30854738

Best ADC Clinical Publication 2019

Winner:
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. PMID: 30516102.

Individual Input to the Field 2019

2019 - 6th World ADC Awards

Best ADC Pre-Clinical Publication

Best Poster 2019

Winner:
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice. Rossin R, Versteegen RM, Wu J, Khasanov A, Wessels HJ, Steenbergen EJ, Ten Hoeve W, Janssen HM, van Onzen AHAM, Hudson PJ, Robillard MS. Nat Commun. 2018 May 4;9(1):1484.

Runner Up:
Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis. Cazzamalli S, Dal Corso A, Widmayer F, Neri D. J Am Chem Soc. 2018 Feb 7;140(5):1617-1621.

Best ADC Clinical Publication

Winner:
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984.

Individual Input to the Field 2018

2018 - 5th World ADC Awards

Individual Input to the Field

Best ADC Publication

Winner: Rovalpituzumab tesirine, a DLL3-targeted antibody-drugconjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCRX16-001 investigators. Lancet Oncol. 2017 Jan;18(1):42-51.

Runner Up: Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. J Clin Oncol. 2017 Jan 10;35(2):141-148.